Aim To report the experience of 23 tertiary referral European Centres on transcatheter closure of congenital ventricular septal defects (VSD).
Introduction
Ventricular septal defects (VSDs) are a common congenital heart disease (approximately 20%). 1 According to their location within the septum, defects can be classified as: muscular, perimembranous, and supracrystal. The most common are the perimembranous VSD (around 70%), while completely muscular VSD may occur in around 15% of the cases. Supracrystal defects are quite rare in Western countries accounting for 5% of all VSD. Rarely, multiple VSDs may be present in a single patient (so called swiss cheese VSDs). Indications to VSD closure are symptoms of heart failure, signs of left heart chambers overload, and history of endocarditis. In patients with an overload of left heart chambers, closure is necessary in order to prevent pulmonary arterial hypertension, ventricular dysfunction, arrhythmias, aortic regurgitation, and development of double-chambered right ventricle.
The traditional treatment is surgical repair, which was performed for the first time by Lillehei et al. 2 in 1954. The surgical approach is considered to be the gold standard, but it is associated with morbidity and mortality, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] patient discomfort, sternotomy, and skin scar.
Percutaneous techniques have been developed in order to reduce the impact of such drawback of surgery.
Since the first VSD closed by a transcatheter approach by Lock et al. 15 various devices and techniques have been used. However, large delivery sheaths were required, complex implantation techniques were needed, and interference with aortic and tricuspid valves and significant residual shunting were quite frequent. [15] [16] [17] [18] [19] [20] [21] [22] [23] Recently, with the introduction of devices of the Amplatzer family (AGA Medical Corp., Golden Valley, MN, USA), this approach appears to be more promising for a routine use. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] The aim of this study is to report data from a European Registry about the percutaneous closure of VSDs performed in 430 patients in 23 European centres.
Methods
The study was conducted as a retrospective study on an intention-to-treat basis. The data was collected from an on-line registry (www.vsdeurope.com) involving 23 European tertiary referral centres (see appendix for list of the centres involved) and it was collected from patients treated until July 2005.
Inclusion and exclusion criteria
The following inclusion criteria were used: (i) isolated defects; (ii) congenital VSD; (iii) residual VSD post-surgical repair of a congenital VSD; (iv) muscular or perimembranous position within the septum; (v) haemodynamically significant VSD (demonstrated by clinical data and echocardiography and/or haemodynamic study and/or angiography); (vi) history of infective endocarditis.
The exclusion criteria were as follows: (i) defects associated with other cardiac lesions needing a surgical approach; (ii) irreversible pulmonary vascular disease (.7 U/m 2 ); (iii) contraindication to antiplatelet therapy; (iv) sepsis; (v) the presence of perimembranous VSD, a subaortic rim as shown by echocardiography in the long axis view ,2 mm.
Four hundred and thirty patients [median age 8 years (range 0.4-70 years), 226 males] underwent an attempt at transcatheter device closure until July 2005. The baseline data are reported in Table 1 .
Data collection
The data was collected prospectively at each participating centre at the time of the procedure by the responsible investigator and it was submitted to a central database at the following website: www. vsdeurope.com.
The data collected included demographic details (date of procedure, age, gender, weight, height), echocardiographic data (VSD position, associated anomalies, aortic, mitral or tricuspid valve regurgitation, subaortic rim in patients with perimembranous VSD), procedural details (access route, sheath size, pulmonary pressures, Qp/Qs, VSD size on angiography, type and measure of device implanted, associated procedures, residual shunting, fluoroscopic, and procedural times). Furthermore, when closure failed, reasons for failure were recorded.
A major complication was defined as an event that resulted in death, long-term sequelae, need for immediate surgery, potentially life-threatening events, persistent arrhythmias needing long-term therapy (.6 months) or pacemaker placement, ongoing haemolysis requiring blood transfusion, thrombosis that required thrombolytic therapy, and increased valvar regurgitation needing device removal or drug therapy.
A minor complication was defined as an event that required drug therapy but was not life-threatening, with no long-term (.6 months) sequelae, and which did not require long-term therapy. The following were also included in this group: device embolization with transcatheter retrieval, haematoma of the groin, cardiac arrhythmias that required cardioversion of drug therapy during the procedure, minor degree atrio-ventricular blocks, and transient loss of peripheral pulse needing only heparin therapy.
Total complications were defined as the sum of minor and major complications.
We defined a complication as early when it occurred during the first month after procedure.
Definition of outcomes Procedural success
Procedural success was defined by device implantation in the appropriate position with no need for surgery (for example due to significant residual shunt or significant valve regurgitation).
Residual shunt
A residual shunt was considered to be present if colour-Doppler flow mapping showed a left to right shunt across the interventricular septum. It was classified as follows; trivial (,1 mm colour jet width), small (1-2 mm colour jet width), moderate (2-4 mm colour jet width), or large (.4 mm colour jet width).
Devices used
The following devices were used: muscular Amplatzer VSD occluder, membranous Amplatzer VSD occluder, PDA Amplatzer occluder, ASD Amplatzer occluder, Starflex device, coil. The details of these devices were previously reported. 
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Closure protocol
Closure protocols for Amplatzer VSD occluders, for Starflex device, and for coil implantation have already been reported. Closure with other device was related to device availability in the centre.
Post-operative care and follow-up
All subjects underwent clinical examination, electrocardiography, chest X-rays, and TTE before discharge and at 1, 6, and 12 months after the procedure and yearly thereafter. Platelet anti-aggregation therapy with aspirin 5 mg/kg/day po and endocarditis prophylaxis were prescribed for 6 months.
Statistical analysis
Data were expressed as a frequency or percentage for nominal variables, as the median (range) for categorical variables and as mean + SD or median (range) for continuous variables. The STATIS-TIX package version 8 was used for the statistical computations.
The following dependent outcome variables were analysed: total complications, complete atrioventricular block (cAVB), embolization, and vascular complications. The following independent variables were included in the analysis: age at procedure, weight at procedure, gender, defect type (congenital, residual post-surgery), defect position (perimembranous, muscular), device type (muscular Amplatzer device, eccentric Amplatzer device, other device), device diameter, complex procedures (yes, no), multiple defects (yes, no), ventricular septal aneurysm (yes, no), device diameter/ defect diameter measured on TTE, device diameter/patient weight.
Univariate analysis was performed using the x 2 test, Fisher's exact test, unpaired Student's t-test, Wilcoxon rank sum test, one-way ANOVA, the Kruskall-Wallis test, log-rank test, Cox regression analysis, logistic regression analysis as appropriate.
Multivariable analysis to study risk factors for the occurrence of early complications was performed using multiple logistic regression analysis. Independent variables with a P-value ,0.2 in the univariate analysis were included in the multivariable model. Odds ratios and their 95% confidence intervals were calculated for independent variables included in the multivariable model.
Multivariable analysis using Cox proportional hazard regression analysis was performed to study the role of independent variables on the occurrence of cAVB in the early period and during the follow-up. Evaluation of proportional hazards assumption was performed using the goodness-of-fit testing approach. 36 All tests were two-sided. A probability value of P , 0.05 was considered statistically significant.
Results
Procedural data
Baseline, procedural data, and devices used are reported in Table 1 .
The procedure was successfully performed in 410 pts (95.3%). The procedure failed in 20 subjects due to the following reasons: technical difficulty in six patients, immediate death in one, need for early surgery in 13 subjects ( Table 2) .
Complex procedures
Combined procedures were performed in 28 subjects (6.5%) ( Table 1) . Post-operative residual defects were treated in 45 patients (10.5%), multiple defects in 16 subjects (3.7%).
Complications
A total of 55 early complications occurred (12.7%). However, significant complication occurred in 28 subjects (6.5%) and are reported in detail below.
Death
Death occurred in one patient during procedure (0.2%). A 6-year-old boy (weight 16 kg) with corrected transposition of the great vessels, dextrocardia, multiple VSD treated with pulmonary artery bending was sent to surgery for double switch, pulmonary artery debanding, and VSD closure. Significant residual VSDs were seen in the postoperative period residual and the patient was sent to the catheterization laboratory to close the residual defects percutaneously. Two muscular Amplatzer devices were implanted (6 and 8 mm). After implantation of the second device the patient experienced fatal cardiac arrest.
Vascular complications
Vascular problems occurred in three subjects (0.7%). All these patients were treated to close a perimembranous VSD using an Amplatzer membranous occluder. They were 3, 3, and 14 years of age, respectively. Two out of three had arterial thrombosis that resolved after r-TPA infusion. Finally, one subject developed aneurysm of the femoral artery needing vascular surgery. Haemolysis (1.2%) and need for blood transfusion Massive haemolysis needing surgical retrieval of the device occurred in a 56-year-old man treated with a 12 mm membranous Amplatzer device. Transient haemolysis needing blood transfusion occurred in two patients (one treated with an 8 mm membranous and one treated with a 10 mm muscular Amplatzer device). In these two subjects, haemolysis resolved spontaneously after 1 and 2 weeks, respectively. Finally in two subjects very mild haemolysis occurred, needing no therapy and resolved spontaneously within the first two days after implantation.
No other subjects needed blood transfusion.
Infection
Infections after procedure occurred in two subjects (0.5%). Post-procedural sepsis occurred in a 3-year-old boy treated for a residual post-surgical VSD with a 10 mm Amplatzer VSD occluder. Endocarditis of the pulmonary valve was evident some days after the procedure in a 2-year-old boy who received the implantation of two muscular Amplatzer VSD occluders for multiple VSDs. In both cases, medical therapy was successfully achieved.
Device embolization
This complication occurred in four cases (0.9%). In three cases it was possible to retrieve the device percutaneously and to implant a larger device. In one case the patient was sent to surgery to retrieve the device and to close the defect.
Arrhythmic complications Tachyarrhythmias
They occurred in three subjects (0.7%). All these patients had a post-operative residual VSD and were adults (32, 56, and 60 years). Two out of these three experienced ventricular tachycardia while one had atrial fibrillation. All subjects were treated by external cardioversion.
Bradyarrhythmias A total of 12 subjects experienced early cAVB (2.8%). Two subjects were sent to surgery because of the occurrence of complete atrioventricular block during implantation of a device in order to close a pmVSD ( Table 3) . In both subjects removal of the device during procedure resulted in restoration of the sinus rhythm. Therefore, operators decided to definitively retrieve the device and to send patients to surgery.
Transient cAVB occurred in four subjects during procedure. Finally, the device was implanted and no rhythmic abnormalities recurred.
In six subjects, cAVB needing PM, implantation occurred within 1 week after implantation. All subjects but two experienced syncope due to asystolia or severe bradycardia.
Analysis of risk factors for the occurrence of complications
Logistic univariate analysis demonstrated that age and weight, were significantly associated with the occurrence of total early complications. In the multivariable logistic regression model, the measure/weight ratio was also included. Multiple logistic regression analysis showed that the only variables associated with a risk of the occurrence of complication were age and weight ( Table 4) .
Valve regurgitation and residual shunt
Complete VSD closure was obtained in 40% at procedure, 65% at discharge, and 83% of patients at follow-up. Residual shunt was defined as trivial in 15% and as mild in 2% of subjects. As previously reported, residual shunt was severe needing surgery in only three cases (0.7%).
In the post-operative period, tricuspid regurgitation was shown in 27 pts (6%) but it was defined as trivial to mild and no treatment was needed. Aortic regurgitation was present in 14 subjects (3.3%), but surgery was needed to remove the device and close the defect in only two patients. 
Follow-up data
The median follow-up was 2 years with a range between 6 months and 10 years. The following complications occurred: sudden death in a patient (1.3 years, 8 kg) 6 weeks after percutaneous muscular VSD closure (10 mm muscular Amplatzer VSD occluder) and surgical pulmonary debanding.
Finally in four subjects, cAVB occurred late (respectively 4, 7, 12, and 18 months after procedure) and they needed PM implantation.
Two patients experienced syncope while two were completely asymptomatic. All these patients were treated for a perimembranous VSD using an Amplatzer perimembranous VSD occluder and were 18-, 31-, 32-months-old, and 36 years, respectively.
Analysis of risk factors for the occurrence of complete AV block
A total of 16 patients experienced cAVB during the period of the study (3.7%) ( Table 3 ). All of them but four had a pmVSD. Two subjects had a muscular VSD, while two more patients had a residual post-surgical defect. This rhythm abnormality occurred early in 12 patients, while in four it was a late event. Pacemaker implantation was needed in 50% of the cases of early cAVB (six of 12) and in 100% of the cases of late cAVB (four of four). Regarding the VSD position, all PM implantations but one were needed in subjects with a perimembranous defect. Infact one patient (1.5 years) had a residual post-surgical VSD. He was previously treated for a perimembranous VSD and the residual defect was located in the higher part of the septum. Finally, all subject needing PM implantation but one were children. Univariate analysis showed that the following variables were significantly associated with the occurrence of cAVB: device type (P ¼ 0.03) and VSD location (P ¼ 0.05).
In the Cox proportional hazard regression analysis, we included age, device type, and VSD location. However, no variable was significantly associated with the occurrence of cAVB.
Discussion
This series reports the largest cohort of patients with congenital VSD who underwent device closure. In fact, 430 subjects were sent to the catheterization laboratory with the intention-to-treat a congenital or residual post-operative congenital VSD.
Success rate was very high because closure was successfully achieved in 95.3% of subjects. This confirms the data reported in literature where the success rate ranges between 87 and 100% of the cases. However, there are some differences between the devices of the Amplatzer family and the Starflex-type devices. In fact, in the latter devices, even if a very high success rate is reported to be up to 99%, 15 surgical explantation of the device is required in around 10% of subjects while with the Amplatzer devices in the European experience it occurs in around 3% of the cases.
Early mortality was very low (0.2%) and it occurred in one patient with a very complex clinical situation. This death rate compares well with the surgical results in which it is between 1 and 5% 4, 5, 8, 9 and to the data reported in literature regarding percutaneous VSD closure. 27 In our report, the total complication rate was 12.5%, however, significant problems occurred in 6.5% of the cases. In the multivariable analysis, the factors associated with the occurrence of complications were age and weight at the time of the procedure.
Percutaneous VSD closure has been reported in literature in around 820 subjects and major complications were described in 0-15% of subjects ( Table 5) . A higher rate of complications was reported in the American trials about percutaneous VSD closure 27 and in subjects treated with the Starflex-type devices. 21 Probably, device-type and the involvement of centres with low experience, may account for the higher rates of severe complications.
Surgery is generally considered a safe procedure for VSD closure, however, it does have some potential risks of complications, including cAVB in 1-5% of the cases, 4, 5, 8, 9 significant residual VSD in 1-10% of the subjects, 5,11-13 the necessity for re-operation in 2% of the patients, 5 and even death in 0.6-5% of the cases. 5, 8, [12] [13] [14] Furthermore, infections, tachyarrhythmias, and neurological complications may occur 5 after surgery. In our experience, the most significant complications were related to conduction abnormalities and in particular to the occurrence of cAVB.
In literature, cAVBs needing pace-maker implantation are reported to occur in 0-8% of subjects (Table 5) . However, the highest rate of occurrence of cAVB occurred in patients treated with the Starflex-type device; 21 and also, this data should to be analysed critically because in most studies, follow-up was not reported. In our experience, cAVB occurred in 16 patients (3.7%). Pace-maker implantations were necessary in 10 subjects (2.3%). Finally in four out of 10 patients this occurred as a late event. Therefore, with a median follow-up of 24 months, cAVB needing PM implantation occurred in 2.3% of the patients treated. Subjects treated with the eccentric Amplatzer device or with other devices (Starflex, coil, ASD Amplatzer, PDA Amplatzer) were at higher risk for this complication. Some authors have suggested that the presence of an aneurysm of ventricular septum or of an oversized device are associated with a higher risk of cAVB. However, our data did not support these statements at all.
Also the occurrence of cAVB after surgery is reported in around 1-5% of cases according to statistics. 4, 5, 8, 9 However, in the current era, even if recently published data is not available, the rate of cAVB is probably at the lowest limit of the range.
However, compared with surgery in which cAVB usually appears early after the operation, in patients treated percutaneously, the occurrence of cAVB is quite unpredictable and it is usually a late problem. This complication is related to the proximity of the conduction system to the margins of the pmVSD. Therefore, both surgery and device implantation may interfere with atrioventricular conduction. Various mechanisms may be considered as causative. It is possible that the presence of the device may disturb atrioventricular conduction by direct traumatic compression. Furthermore, the device may give rise to an inflammatory reaction or scar formation in the conduction tissue. However, there are is no specific data about the mechanisms involved in the occurrence of cAVB after percutaneous closure of a pmVSD. Large studies are needed to clarify the real impact of arrhythmic problems in these patients and the mechanism of the events.
Conclusions
In the current era and in experienced centres, percutaneous VSD closure provides a valuable alternative to surgery even in cases with complex morphology and in very young children.
Finally, due to the late occurrence of cAVB, careful monitoring of rhythm and atrioventricular conduction is essential during follow-up, especially in the case of subjects treated for a perimembranous VSD.
